Vanguard VaultClient Vault
John Doe44 · MaleVV-2026-0417

Labs analysis

Your biomarkers

Your results are ranged against longevity targets and laboratory reference intervals. The 53 priority markers below include the full values and clinical interpretation from your 153-marker panel.

Baseline · 12 March 2026Follow-up · 9 September 2026

Blood biomarkers

82

Optimal

54

In range

17

Out of range

153 markers tested - latest panel released 12 September 2026

Markers moved into optimal

44

of 53 priority markers

Out of range at baseline

6

flagged for intervention

Out of range at follow-up

0

remaining watch items

Chain of review - Comprehensive Baseline Panel - 153 markers

Released
  1. 1

    Specimen received

    13 March 2026

    Precision Analytics Laboratory

  2. 2

    Reviewed & signed

    16 March 2026 · 09:42

    Dr. Alan R. Whitfield, MD - Internal Medicine · Longevity Medicine

  3. 3

    Released to patient

    16 March 2026

    Visible in the client Vault

Signature on file

A. R. Whitfield

License #IM-448120

Chain of review - Follow-up Panel - 153 markers

Released
  1. 1

    Specimen received

    10 September 2026

    Precision Analytics Laboratory

  2. 2

    Reviewed & signed

    12 September 2026 · 08:15

    Dr. Alan R. Whitfield, MD - Internal Medicine · Longevity Medicine

  3. 3

    Released to patient

    12 September 2026

    Visible in the client Vault

Signature on file

A. R. Whitfield

License #IM-448120

Result ranges

  • Laboratory reference interval.
  • Your clinical target range.
  • Hollow pin - baseline result in March.
  • Solid pin - follow-up result in September.

Endocrine - full axis

Testosterone axis

The whole axis, not just total testosterone: binding proteins, pituitary signalling, aromatisation and downstream androgens.

Total testosterone

ng/dL

Moved to optimalOptimal
264optimal 700-950916
Baseline 412 (inrange), follow-up 782 (optimal) ng/dL

Baseline

412

Follow-up

782

Change

+370+90%

Free testosterone

pg/mL

Moved to optimalOptimal
46optimal 150-220224
Baseline 61 (inrange), follow-up 168 (optimal) pg/mL

Baseline

61

Follow-up

168

Change

+107+175%

Bioavailable testosterone

ng/dL

Moved to optimalOptimal
110optimal 300-500575
Baseline 148 (inrange), follow-up 361 (optimal) ng/dL

Baseline

148

Follow-up

361

Change

+213+144%

SHBG

nmol/L

Moved to optimalOptimal
16optimal 20-3555
Baseline 52 (inrange), follow-up 33 (optimal) nmol/L

Baseline

52

Follow-up

33

Change

−19−37%

Albumin

g/dL

Moved to optimalOptimal
3.5optimal 4.3-55.2
Baseline 4.1 (inrange), follow-up 4.6 (optimal) g/dL

Baseline

4.1

Follow-up

4.6

Change

+0.5+12%

Free androgen index

ratio

Moved to optimalOptimal
24optimal 55-100104
Baseline 27 (inrange), follow-up 82 (optimal) ratio

Baseline

27

Follow-up

82

Change

+55+204%

LH

IU/L

Moved to optimalOptimal
1.7optimal 3-68.6
Baseline 2.1 (inrange), follow-up 4.4 (optimal) IU/L

Baseline

2.1

Follow-up

4.4

Change

+2.30+110%

FSH

IU/L

Optimal
1.5optimal 2-612.4
Baseline 2.4 (optimal), follow-up 3.6 (optimal) IU/L

Baseline

2.4

Follow-up

3.6

Change

+1.20+50%

Estradiol (sensitive)

pg/mL

Moved to optimalOptimal
8optimal 20-3043
Baseline 14 (inrange), follow-up 26 (optimal) pg/mL

Baseline

14

Follow-up

26

Change

+12+86%

Testosterone : estradiol ratio

ratio

Optimal
-optimal 20-35-
Baseline 29.4 (optimal), follow-up 30.1 (optimal) ratio

Baseline

29.4

Follow-up

30.1

Change

+0.70+2%

DHEA-S

µg/dL

Moved to optimalOptimal
106optimal 350-500464
Baseline 188 (inrange), follow-up 372 (optimal) µg/dL

Baseline

188

Follow-up

372

Change

+184+98%

Prolactin

ng/mL

Moved to optimalOptimal
4optimal 4-1015.2
Baseline 13.8 (inrange), follow-up 8.1 (optimal) ng/mL

Baseline

13.8

Follow-up

8.1

Change

−5.70−41%

Progesterone

ng/mL

Moved to optimalOptimal
0.1optimal 0.2-0.50.5
Baseline 0.14 (inrange), follow-up 0.31 (optimal) ng/mL

Baseline

0.14

Follow-up

0.31

Change

+0.17+121%

PSA, total

ng/mL

Optimal
0optimal 0-1.54
Baseline 0.8 (optimal), follow-up 0.9 (optimal) ng/mL

Baseline

0.8

Follow-up

0.9

Change

+0.10+12%

Clinical evaluation

Dr. Alan R. Whitfield, MD

What the numbers said

At baseline John presented with low-normal total testosterone and genuinely low free testosterone, driven by high SHBG binding most of what he produced. LH sat at the bottom of range, so the pituitary was not pushing the testes hard. Prolactin was borderline high, which suppresses that signal further.

Why it matters

Free testosterone - not total - is what reaches tissue. In this range men report flat drive, poor recovery between training sessions, visceral fat that will not move, and worsening insulin sensitivity. Left alone the axis usually drifts further with age.

What changed by follow-up

Free testosterone rose from 61 to 168 pg/mL with SHBG down from 52 to 33 nmol/L, LH restored into mid-range, prolactin normalised, and estradiol brought up into the protective 20-30 pg/mL window rather than crushed. The T:E2 ratio was deliberately held stable.

What we did

Sleep and circadian correction first, then insulin-sensitivity work through nutrition, resistance training three times weekly with progressive overload, boron and zinc to reduce SHBG binding, and physician-supervised axis support with monthly monitoring.

Longevity - atherogenic burden

Cardiovascular risk

Particle-based risk, not just a standard cholesterol panel. ApoB and Lp(a) drive lifetime cardiovascular exposure.

ApoB

mg/dL

In range
40optimal 40-70125
Baseline 118 (inrange), follow-up 71 (inrange) mg/dL

Baseline

118

Follow-up

71

Change

−47−40%

Lp(a)

nmol/L

Optimal
0optimal 0-5075
Baseline 46 (optimal), follow-up 44 (optimal) nmol/L

Baseline

46

Follow-up

44

Change

−2−4%

Largely genetic - tracked, not chased.

LDL particle number

nmol/L

Moved to optimalOptimal
0optimal 0-10001260
Baseline 1486 (out), follow-up 940 (optimal) nmol/L

Baseline

1486

Follow-up

940

Change

−546−37%

LDL cholesterol

mg/dL

In range
0optimal 0-80100
Baseline 142 (out), follow-up 84 (inrange) mg/dL

Baseline

142

Follow-up

84

Change

−58−41%

HDL cholesterol

mg/dL

Moved to optimalOptimal
40optimal 55-9090
Baseline 42 (inrange), follow-up 58 (optimal) mg/dL

Baseline

42

Follow-up

58

Change

+16+38%

Triglycerides

mg/dL

Moved to optimalOptimal
0optimal 0-80150
Baseline 186 (out), follow-up 74 (optimal) mg/dL

Baseline

186

Follow-up

74

Change

−112−60%

Triglyceride : HDL ratio

ratio

Moved to optimalOptimal
-optimal 0-1.5-
Baseline 4.4 (inrange), follow-up 1.3 (optimal) ratio

Baseline

4.4

Follow-up

1.3

Change

−3.10−70%

Remnant cholesterol

mg/dL

Moved to optimalOptimal
0optimal 0-1530
Baseline 34 (out), follow-up 13 (optimal) mg/dL

Baseline

34

Follow-up

13

Change

−21−62%

Omega-3 index

%

Moved to optimalOptimal
2optimal 8-1212
Baseline 4.2 (inrange), follow-up 8.9 (optimal) %

Baseline

4.2

Follow-up

8.9

Change

+4.7+112%

Clinical evaluation

Dr. Alan R. Whitfield, MD

What the numbers said

Baseline showed an atherogenic pattern: ApoB 118 mg/dL with LDL particle number well above range, triglycerides high and HDL low - the classic insulin-resistant lipid signature rather than a purely dietary-cholesterol picture.

Why it matters

ApoB counts the number of artery-penetrating particles. Cumulative ApoB exposure over decades is the single strongest modifiable driver of cardiovascular events. Trig:HDL above 3 also flags insulin resistance years before glucose moves.

What changed by follow-up

ApoB fell 47 mg/dL into the optimal band, triglycerides more than halved, Trig:HDL dropped from 4.4 to 1.3, and the omega-3 index moved from deficient to protective. Lp(a) is genetically set and unchanged - it stays on the watch list and raises the target aggressiveness for everything else.

What we did

Carbohydrate quality and timing restructured around training, saturated fat reduced in favour of monounsaturated sources, 3 g/day EPA/DHA, zone-2 cardio four hours weekly, and a repeat particle panel at 90 days before any pharmacological step was considered.

Longevity - glycaemic control

Metabolic & inflammatory

Insulin resistance and systemic inflammation - the two engines behind most age-related decline.

Fasting insulin

µIU/mL

Moved to optimalOptimal
2.6optimal 2-524.9
Baseline 14.2 (inrange), follow-up 4.6 (optimal) µIU/mL

Baseline

14.2

Follow-up

4.6

Change

−9.6−68%

HOMA-IR

index

Moved to optimalOptimal
0optimal 0-1.22.9
Baseline 3.4 (out), follow-up 1 (optimal) index

Baseline

3.4

Follow-up

1

Change

−2.4−71%

Fasting glucose

mg/dL

Moved to optimalOptimal
70optimal 75-8899
Baseline 98 (inrange), follow-up 86 (optimal) mg/dL

Baseline

98

Follow-up

86

Change

−12−12%

HbA1c

%

Moved to optimalOptimal
4optimal 4.6-5.25.6
Baseline 5.6 (inrange), follow-up 5.1 (optimal) %

Baseline

5.6

Follow-up

5.1

Change

−0.5−9%

hs-CRP

mg/L

Moved to optimalOptimal
0optimal 0-0.63
Baseline 2.8 (inrange), follow-up 0.5 (optimal) mg/L

Baseline

2.8

Follow-up

0.5

Change

−2.3−82%

Homocysteine

µmol/L

Moved to optimalOptimal
4optimal 5-815
Baseline 12.4 (inrange), follow-up 7.6 (optimal) µmol/L

Baseline

12.4

Follow-up

7.6

Change

−4.80−39%

Uric acid

mg/dL

Moved to optimalOptimal
3.4optimal 3.5-5.57
Baseline 6.9 (inrange), follow-up 5.2 (optimal) mg/dL

Baseline

6.9

Follow-up

5.2

Change

−1.7−25%

IGF-1

ng/mL

Moved to optimalOptimal
63optimal 120-180223
Baseline 96 (inrange), follow-up 148 (optimal) ng/mL

Baseline

96

Follow-up

148

Change

+52+54%

Leptin

ng/mL

Moved to optimalOptimal
0.5optimal 1-512.5
Baseline 11.8 (inrange), follow-up 4.1 (optimal) ng/mL

Baseline

11.8

Follow-up

4.1

Change

−7.70−65%

Clinical evaluation

Dr. Alan R. Whitfield, MD

What the numbers said

HOMA-IR of 3.4 with fasting insulin at 14.2 µIU/mL placed John firmly in insulin resistance despite a glucose and HbA1c a standard physical would have called normal. hs-CRP and homocysteine confirmed low-grade systemic inflammation.

Why it matters

Insulin resistance precedes type 2 diabetes by a decade or more and is simultaneously suppressing the testosterone axis, raising ApoB and accelerating biological ageing. This is where most of the leverage is.

What changed by follow-up

Fasting insulin down 68%, HOMA-IR into the optimal band, hs-CRP down to 0.5 mg/L, homocysteine normalised, and IGF-1 lifted from the low end into the mid-range target rather than pushed high.

What we did

Protein-forward meal structure with a 12-hour eating window, post-meal walking, resistance training as the primary glucose-disposal tool, methylated B-complex for homocysteine, and magnesium repletion.

Systems - capacity and clearance

Organ function & thyroid

Liver, kidney and thyroid capacity - the systems that must tolerate any protocol before it is escalated.

ALT

U/L

Moved to optimalOptimal
7optimal 10-2552
Baseline 44 (inrange), follow-up 22 (optimal) U/L

Baseline

44

Follow-up

22

Change

−22−50%

AST

U/L

Moved to optimalOptimal
13optimal 15-2639
Baseline 34 (inrange), follow-up 24 (optimal) U/L

Baseline

34

Follow-up

24

Change

−10−29%

GGT

U/L

Moved to optimalOptimal
9optimal 10-2048
Baseline 41 (inrange), follow-up 18 (optimal) U/L

Baseline

41

Follow-up

18

Change

−23−56%

eGFR

mL/min/1.73

Moved to optimalOptimal
60optimal 90-120120
Baseline 88 (inrange), follow-up 98 (optimal) mL/min/1.73

Baseline

88

Follow-up

98

Change

+10+11%

Cystatin C

mg/L

Moved to optimalOptimal
0.5optimal 0.5-0.81
Baseline 0.94 (inrange), follow-up 0.78 (optimal) mg/L

Baseline

0.94

Follow-up

0.78

Change

−0.16−17%

Albumin : creatinine ratio

mg/g

Moved to optimalOptimal
0optimal 0-1030
Baseline 14 (inrange), follow-up 6 (optimal) mg/g

Baseline

14

Follow-up

6

Change

−8−57%

TSH

mIU/L

Moved to optimalOptimal
0.45optimal 0.8-24.5
Baseline 3.2 (inrange), follow-up 1.6 (optimal) mIU/L

Baseline

3.2

Follow-up

1.6

Change

−1.6−50%

Free T3

pg/mL

Moved to optimalOptimal
2.3optimal 3.2-4.24.2
Baseline 2.6 (inrange), follow-up 3.5 (optimal) pg/mL

Baseline

2.6

Follow-up

3.5

Change

+0.9+35%

Free T4

ng/dL

Moved to optimalOptimal
0.8optimal 1.1-1.61.8
Baseline 1 (inrange), follow-up 1.3 (optimal) ng/dL

Baseline

1

Follow-up

1.3

Change

+0.30+30%

Reverse T3

ng/dL

Moved to optimalOptimal
8optimal 8-1525
Baseline 22 (inrange), follow-up 13 (optimal) ng/dL

Baseline

22

Follow-up

13

Change

−9−41%

Clinical evaluation

Dr. Alan R. Whitfield, MD

What the numbers said

GGT and ALT elevated together with a high reverse T3 and low free T3 - a pattern of hepatic fat and a body downshifting its own thyroid conversion under metabolic and sleep stress, not primary thyroid disease.

Why it matters

Reverse T3 rising while free T3 falls is the body throttling metabolic rate. Treating it as a thyroid problem misses the cause. Kidney filtration measured by cystatin C rather than creatinine alone gives a truer picture in a muscular client.

What changed by follow-up

GGT more than halved, ALT and AST into the optimal band, free T3 up to 3.5 pg/mL with reverse T3 down to 13, and cystatin C-derived filtration improved. No thyroid medication was used.

What we did

Alcohol removed for the first 90 days, hepatic fat addressed through the metabolic protocol, selenium and iodine sufficiency confirmed, sleep extended to 7.5 hours, and training volume periodised to reduce chronic stress load.

Foundations - substrate availability

Micronutrients & blood

The raw materials the protocol depends on. A deficient substrate caps every other result.

Vitamin D, 25-OH

ng/mL

Moved to optimalOptimal
30optimal 50-80100
Baseline 22 (out), follow-up 62 (optimal) ng/mL

Baseline

22

Follow-up

62

Change

+40+182%

Vitamin B12

pg/mL

Moved to optimalOptimal
232optimal 500-9001245
Baseline 318 (inrange), follow-up 664 (optimal) pg/mL

Baseline

318

Follow-up

664

Change

+346+109%

Folate, serum

ng/mL

Moved to optimalOptimal
3.4optimal 10-2020
Baseline 6.1 (inrange), follow-up 14.2 (optimal) ng/mL

Baseline

6.1

Follow-up

14.2

Change

+8.1+133%

Magnesium, RBC

mg/dL

Moved to optimalOptimal
4optimal 5.6-6.46.4
Baseline 4.4 (inrange), follow-up 5.9 (optimal) mg/dL

Baseline

4.4

Follow-up

5.9

Change

+1.5+34%

Zinc, plasma

µg/dL

Moved to optimalOptimal
60optimal 90-130130
Baseline 71 (inrange), follow-up 104 (optimal) µg/dL

Baseline

71

Follow-up

104

Change

+33+46%

Ferritin

ng/mL

Moved to optimalOptimal
30optimal 50-150400
Baseline 214 (inrange), follow-up 118 (optimal) ng/mL

Baseline

214

Follow-up

118

Change

−96−45%

Transferrin saturation

%

Moved to optimalOptimal
15optimal 25-4050
Baseline 47 (inrange), follow-up 33 (optimal) %

Baseline

47

Follow-up

33

Change

−14−30%

Haemoglobin

g/dL

Optimal
13.2optimal 14-16.517.1
Baseline 14.6 (optimal), follow-up 15.4 (optimal) g/dL

Baseline

14.6

Follow-up

15.4

Change

+0.80+5%

Haematocrit

%

Optimal
38.5optimal 42-4850
Baseline 43.1 (optimal), follow-up 46.2 (optimal) %

Baseline

43.1

Follow-up

46.2

Change

+3.10+7%

White cell count

K/µL

Moved to optimalOptimal
3.4optimal 4-710.8
Baseline 7.9 (inrange), follow-up 5.6 (optimal) K/µL

Baseline

7.9

Follow-up

5.6

Change

−2.30−29%

Platelets

K/µL

Optimal
150optimal 180-320450
Baseline 289 (optimal), follow-up 264 (optimal) K/µL

Baseline

289

Follow-up

264

Change

−25−9%

Clinical evaluation

Dr. Alan R. Whitfield, MD

What the numbers said

Vitamin D frankly deficient at 22 ng/mL, RBC magnesium and zinc both low, and ferritin with transferrin saturation running high - iron loading rather than iron deficiency.

Why it matters

Low D and zinc directly limit androgen production and immune function; low RBC magnesium limits sleep quality and glucose handling. High ferritin with high saturation is an oxidative-stress load that quietly accelerates ageing.

What changed by follow-up

Vitamin D into the 50-80 ng/mL target, magnesium and zinc repleted, ferritin brought from 214 to 118 ng/mL with saturation normalised. Haemoglobin and haematocrit stayed inside the safe band throughout axis support - monitored specifically for that reason.

What we did

Vitamin D3 with K2 titrated to level, magnesium glycinate at night, zinc with copper balance, dietary iron moderated with two supervised blood donations, and quarterly re-testing.